{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:03:13Z","timestamp":1789012993751,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"MajesTEC-1 was funded by Janssen Research & Development, LLC"},{"name":"LocoMMotion was funded by Janssen Research & Development, LLC and Legend Biotech, Inc."},{"DOI":"10.13039\/501100014064","name":"Universidad de Salamanca","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014064","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s12325-023-02480-7","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T10:03:04Z","timestamp":1679652184000},"page":"2412-2425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and\/or Refractory Multiple Myeloma"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct04035226","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Philippe","family":"Moreau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ghilotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Diels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elsada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Strulev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Slavcev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"2480_CR1","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","volume":"25","author":"RZ Orlowski","year":"2007","unstructured":"Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892\u2013901.","journal-title":"J Clin Oncol"},{"key":"2480_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. EHA Guidelines Committee; multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol."},{"key":"2480_CR3","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.3747\/co.20.1252","volume":"20","author":"C Chen","year":"2013","unstructured":"Chen C, Baldassarre F, Kanjeekal S, Herst J, Hicks L, Cheung M. Lenalidomide in multiple myeloma\u2014a practice guideline. Curr Oncol. 2013;20:e136\u201349.","journal-title":"Curr Oncol"},{"key":"2480_CR4","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","volume":"4","author":"F Gay","year":"2018","unstructured":"Gay F, Jackson G, Rosi\u00f1ol L, et al. Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis. JAMA Oncol. 2018;4:1389\u201397.","journal-title":"JAMA Oncol"},{"key":"2480_CR5","doi-asserted-by":"crossref","first-page":"117822421986823","DOI":"10.1177\/1178224219868235","volume":"13","author":"SA Bird","year":"2019","unstructured":"Bird SA, Boyd K. Multiple myeloma: an overview of management. Palliat Care Soc Pract. 2019;13:1178224219868235.","journal-title":"Palliat Care Soc Pract"},{"key":"2480_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","volume":"128","author":"SZ Usmani","year":"2016","unstructured":"Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128:37\u201344.","journal-title":"Blood"},{"key":"2480_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","volume":"175","author":"MS Raab","year":"2016","unstructured":"Raab MS, Cavo M, Delforge M, et al. Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016;175:66\u201376.","journal-title":"Br J Haematol"},{"key":"2480_CR8","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.5045\/br.2020.S008","volume":"55","author":"JH Lee","year":"2020","unstructured":"Lee JH, Kim S-H. Treatment of relapsed and refractory multiple myeloma. Blood Res. 2020;55:S43-53.","journal-title":"Blood Res"},{"key":"2480_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100808","volume":"49","author":"K Ramasamy","year":"2021","unstructured":"Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos MV, Richardson P. Improving outcomes for patients with relapsed multiple myeloma: challenges and considerations of current and emerging treatment options. Blood Rev. 2021;49: 100808.","journal-title":"Blood Rev"},{"key":"2480_CR10","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375.","journal-title":"Leukemia"},{"key":"2480_CR11","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1016\/j.clml.2020.12.023","volume":"21","author":"V Kumar","year":"2021","unstructured":"Kumar V, Ailawadhi M, Dutta N, et al. Trends in early mortality from multiple myeloma: a population-based analysis. Clin Lymphoma Myeloma Leuk. 2021;21:e449\u201355.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2480_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"70","author":"P Robak","year":"2018","unstructured":"Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199\u2013208.","journal-title":"Cancer Treat Rev"},{"key":"2480_CR13","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Powers G, Luistro L, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020;4:4538\u201349.","journal-title":"Blood Adv"},{"key":"2480_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ, et al. Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398:665\u201374.","journal-title":"Lancet"},{"key":"2480_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"2480_CR16","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/ajh.25963","volume":"95","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Kumar SK, Usmani SZ, et al. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma. Am J Hematol. 2020;95:1486\u201394.","journal-title":"Am J Hematol"},{"key":"2480_CR17","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"M-V Mateos","year":"2022","unstructured":"Mateos M-V, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36:1371\u20136.","journal-title":"Leukemia"},{"key":"2480_CR18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","volume":"113","author":"F Li","year":"2018","unstructured":"Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113:390\u2013400.","journal-title":"J Am Stat Assoc"},{"key":"2480_CR19","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083\u2013107.","journal-title":"Stat Med"},{"key":"2480_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/10428194.2018.1459609","volume":"60","author":"S Kumar","year":"2019","unstructured":"Kumar S, Durie B, Nahi H, et al. Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. Leuk Lymphoma. 2019;60:163\u201371.","journal-title":"Leuk Lymphoma"},{"key":"2480_CR21","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","volume":"114","author":"J-L Harousseau","year":"2009","unstructured":"Harousseau J-L, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood. 2009;114:3139\u201346.","journal-title":"Blood"},{"key":"2480_CR22","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381:727\u201338.","journal-title":"N Engl J Med"},{"key":"2480_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207\u201321.","journal-title":"Lancet Oncol"},{"key":"2480_CR24","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2480_CR25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02480-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02480-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02480-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T19:15:55Z","timestamp":1682450155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02480-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2480"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02480-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]},"assertion":[{"value":"6 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}